Secukinumab Provides Higher Symptomatic Improvement Versus Adalimumab in Psoriatic Arthritis- Comparative Effectiveness Up to 48 Weeks Assessed by two Matching-Adjusted indirect Comparisons

Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2958
https://www.valueinhealthjournal.com/article/S1098-3015(17)33292-8/fulltext
Title : Secukinumab Provides Higher Symptomatic Improvement Versus Adalimumab in Psoriatic Arthritis- Comparative Effectiveness Up to 48 Weeks Assessed by two Matching-Adjusted indirect Comparisons
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33292-8&doi=10.1016/j.jval.2017.08.2958
First page : A935
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 2707
Categories :
Tags :
Regions :
ViH Article Tags :